Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-06-27
2006-06-27
Moran, Marjorie A. (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S192000
Reexamination Certificate
active
07067500
ABSTRACT:
The present invention is directed to methods of antimicrobial therapy for a patient infected with, or suspected of being infected with a microorganism that has mycolic acid structures in its outer membrane, said method comprising coadministering a betaine-like detergent and an antibiotic to said patient in an amount and for a length of time sufficient to kill said microorganism.
REFERENCES:
patent: 3937655 (1976-02-01), Pfeiffer et al.
patent: 3987053 (1976-10-01), Cavalleri et al.
patent: 4075350 (1978-02-01), Michaels
patent: 4107328 (1978-08-01), Michaels
patent: 4622297 (1986-11-01), Kappner et al.
patent: 5399558 (1995-03-01), Baker et al.
patent: 5523288 (1996-06-01), Cohen et al.
patent: 5543417 (1996-08-01), Waldstreicher
patent: 5610198 (1997-03-01), Barry, III et al.
patent: 5629288 (1997-05-01), Lattrell et al.
patent: 5658749 (1997-08-01), Thornton
patent: 5834473 (1998-11-01), Virtanen et al.
patent: 6242486 (2001-06-01), Thornton et al.
patent: 07196408 (1995-08-01), None
patent: WO 95/27076 (1995-10-01), None
patent: WO 98/50576 (1998-11-01), None
Brennan, P.J., “The Envelope of Mycobacteria,”Annu. Rev. Biochem. 64:29-63, Annual Reviews, Inc. (1995).
Chambers, H.F., et al., “Can Penicillins and Other β-Lactam Antibiotics Be Used To Treat Tuberculosis?”Antimicrob. Agents Chemother. 39:2620-2624, American Society for Microbiology (1995).
Connell, N.D. and Nikaido, H., “Chapter 22: Membrane Permeability and Transport inMycobacterium tuberculosis,” in:Tuberculosis: Pathogenesis, Protection, and Control, Bloom, B.R., ed., American Society for Microbiology, Washington, D.C., pp. 333-352 (1994).
Cynamon, M.H. and Klemens, S.P., “Chapter 5: Drug Susceptibility Tests forMycobacterium fortuitumandMycobacterium chelonae,” in:Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, Heifets, L.B., ed., CRC Press, Boca Raton, Florida, pp. 147-159 (1991).
Dubos, R.J. and Davis, B.D., “Factors Affecting the Growth of Tubercle Bacilli in Liquid Media,”J. Exp. Med. 83:409-423, Rockefeller Institute for Medical Research (1946).
Eng, R.H.K., et al., “Inoculum Effect of New β-Lactam Antibiotics onPseudomonas aeruginosa,” Antimicrob. Agents Chemother. 26:42-47, American Society for Microbiology (1984).
Heifets, L.B., “Chapter 1: Antituberculosis Drugs: Antimicrobial Activity In Vitro,” in:Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, Heifets, L.B., ed., CRC Press, Boca Raton, Florida, pp. 13-57 (1991).
Hugo, W.B., “Some Aspects of the Action of Cationic Surface-Active Agents on Microbial Cells with Special Reference to Their Action on Enzymes,” in:Surface Activity and the Microbial Cell, Staples Printers Ltd., Rochester, England, pp. 67-83 (1965).
Hui, J., et al., “Permeability Barrier to Rifampin in Mycobacteria,”Antimicrob. Agents Chemother. 11:773-779, American Society for Microbiology (1977).
Inderlied, C.B. and Salfinger, M., “Antimicrobial Agents and Susceptibility Test: Mycobacteria,” in:Manual of Clinical Microbiology, Murray, P.R. et al., eds., ASM Press Washington, D.C., pp. 1385-1404 (1995).
Jarlier, V. and Nikaido, H., “Permeability Barrier to Hydophilic Solutes inMycobacterium chelonei,” J. Bacteriol. 172:1418-1423, American Society for Microbiology (1990).
Jorgensen, J.H. and Sahm, D.F., “Antimicrobial Susceptibility Testing: General Considerations,” in:Manual of Clinical Microbiology, Murray, P.R. et al., eds., ASM Press Washington, D.C., pp. 1277-1280 (1995).
Liu, J., et al., “Mycolic Acid Structure Determines the Fluidity of the Mycobacterial Cell Wall,”J. Biol. Chem. 271:29545-29551, American Society for Biochemistry and Molecular Biology, Inc. (Nov. 1996).
National Committee for Laboratory Standards, “Development ofIn VitroSusceptibility Testing Criteria and Quality Control Parameters; Approved Guideline,” NCCLS Document M23-A, Villanova, PA (1994).
National Committee for Laboratory Standards, “Performance Standards for Antimicrobial Disk Suscebtibility Tests-Sixth Edition; Approved Standard,” NCCLS Document M2-A6, Villanova, PA (Jan. 1997).
National Committee for Laboratory Standards, “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically- Fourth Edition; Approved Standard,” NCCLS Document M7-A4, Villanova, PA (Jan. 1997).
Nikaido, H. and Jarlier, V., “Permeability of the mycobacterial cell wall,”Res. Microbiol. 142:437-443, Elsevier Science (1991).
Rastogi, N., et al., “Enhancement of Drug Susceptibility ofMicrobacterium aviumby Inhibitors of Cell Envelope Synthesis,”Antimicrob. Agents Chemother. 34:759-764, American Society for Microbiology (1990).
Roberts, G.D., et al., “Evaluation of the BACTEC Radiometric Method for Recovery of Mycobacteria and Drug Susceptibility testing ofMycobacterium tuberculosisfrom Acid-Fast Smear-Positive Specimens,”J. Clin. Microbiol. 18:689-696, American Society for Microbiology (1983).
Siddiqi, S.H., et al., “Evaluation of a Rapid Radiometric Method for Drug Susceptibility Testing ofMycobacterium tuberculosis,” J. Clin. Microbiol. 13:908-912, American Society for Microbiology (1981).
Snider Jr., D.E., et al., “Rapid Drug-Susceptibility Testing ofMycobacterium tuberculosis,” Am. Rev. Respir. Dis. 123:402-406, American Lung Association (1981).
Stinson, M.W., et al., Interaction of Tween 80 Detergent with Mycobacteria in Synthetic Medium,Am. Rev. Respir. Dis. 104:717-727, American Lung Association (1971).
Tarrand, J.L. and Gröschel, D.H.M., “Evaluation of the BACTEC Radiometric Method for Detection of 1% Resistant Populations ofMycobacterium tuberculosis,” J. Clin. Microbiol. 21:941-946, American Society for Microbiology (1985).
Tsubone, K., et al., “Relation between Structure and Antimicrobial Activity of 2-(N,N,N-Trialkylammonio)alkyl HydrogenPhosphates,”J. Pharm Sci. 80:441-444, American Pharmaceutical Association (1991).
Tsubone, K., “Correlation between Antimicrobial Activity and Chelating Ability of 2-(N,N,N-Trialkylammonio)alkyl HydrogenPhosphates,”J. Pharm. Sci. 80:1051-1054, American Pharmaceutical Association (1991).
Vincké, G., et al., “Rapid Susceptibility ofMycobacterium tuberculosisby a radiometric technique,”J. Antimicrob. Chemother. 10:351-354, Academic Press, Inc. (1982).
Woods, G.L. and Washington, J.A., “Antibacterial Susceptibility Tests: Dilution and Disk Diffusion Methods,” in:Manual of Clinical Microbiology, Murray, P.R. et al., eds., ASM Press Washington, D.C., pp. 1327-1384 (1995).
Yamori, S. and Tsukamura, M., “Paradoxical Effect of Tween 80 between the Susceptibility to Rifampicin and Streptomycin and the Susceptibility to Ethambutol and Sulfadimethoxine in theMycobacterium avium- Mycobacterium intracellulareComplex,”Microbiol. Immunol. 35:921-926, Center for Academic Publications Japan (1991).
Supplementary European Search Report for European Application No. EP 98 92 0928, European Patent Office, Netherlands, received on Sep. 13, 2004.
Integrated Research Technology, LLC
Moran Marjorie A.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Betaines as adjuvants to susceptibility testing and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Betaines as adjuvants to susceptibility testing and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Betaines as adjuvants to susceptibility testing and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3656524